Curious anomalies in vaccine effectiveness during the 2012/2013 flu season
The 2012/2013 influenza season is winding down now in North America, Europe and other Northern hemisphere locations, and interim estimates for vaccine effectiveness are now available from multiple sources [1, 2, 3, 4] . The most striking statistic reported [3, 4] is that the vaccine displayed extremely low effectiveness against A/H3N2 in the elderly. This data has significant implications for future vaccine design, influenza surveillance, and treatment of the elderly during influenza outbreaks and epidemics.
In the early months of each year, the Centers for Disease Control in Atlanta and the World Health Organization make recommendations for the vaccine strains of influenza to be used by vaccine producers for manufacturing influenza vaccines [5] in the northern hemisphere for use in the following influenza season. In the absence of a pandemic, usually three strains of influenza are chosen for vaccine production: two influenza A viruses, one from the H1N1 subtype and one from the H3N2 subtype, and one B influenza [5] .
The 2012/2013 influenza season was early and moderately severe in the United States [6] . The predominant circulating strains were antigenically similar to A/Victoria/2011-like (H3N2) and B/Wisconsin/1/2010-like (69% of the B viruses detected, Yamagata lineage) and B/Victoria (31% of the B viruses detected, Victoria lineage). The early flu season allowed for interim vaccine effectiveness casecontrol studies to be determined for Canada [1] , the United Kingdom [2] , Denmark [3] and the United States [4] . The studies from Canada, the United States, and the United Kingdom have similar overall vaccine effectiveness for all influenza strains across the entire population (see Table 1 ). The effectiveness ranged from 38% to 49% for A viruses and 46% to 50% for all influenza viruses. B virus effectiveness was 52% and 67% respectively for the United Kingdom and the United States.
These numbers for the general population are not so surprising and appear on the surface to be in line with what has been reported for previous years. The disturbing statistic is evident when effectiveness is broken down for age ( Table 2 ). The studies from the United States [4] and Denmark [3] both show that vaccine effectiveness in the elderly ( > 65 years of age) is extremely low (see last row of Table 2 ). What is even more perplexing is that the younger age groups in the American study show between 46% and 58% vaccine effectiveness against H3N2, validating that the vaccine can elicit protective responses, at least in people younger than 65 years of age. Furthermore, the elderly group in both the American study and the Danish studies show that vaccine effectiveness against B viruses was relatively high at 69% and 67% for the two countries (Table 2) .
Why is the H3N2 vaccine effectiveness so low in the elderly for the 2012/2013 season?
Part of the answer to this question may reside in antigenic changes identified in the HA1 gene of the H3N2 viruses that circulated in Canada and Denmark [1, 3] . Skowronski and colleagues [1] and Bragstad and colleagues [3] both identified numerous mutations in the antigenic regions of the HA gene, thereby constituting a possible antigenic drift of the A/Victoria/361/2011 (H3N2)-like virus to the present circulating H3N2 strains in North America and Europe. Antigenic studies will provide insight into this possibility.
Interestingly, the antigenic shift does not explain everything; the vaccine was still capable of eliciting effective immune responses against H3N2 in the young. A simple interpretation of this data is that the elderly generate a narrow antibody response to the vaccine strain of H3N2 which is not capable of protecting against a H3N2 virus with shifted antigenicity. Moreover, younger vaccinated people likely generate an immune response with greater breadth which can protect against shifted viruses. If this is so, how can vaccine manufacturers create a vaccine that brings out a larger breadth of antibody responses? Many adjuvants currently await testing, but we must learn more about the immune system in the elderly to design more effective vaccines. We must avoid a random sampling of adjuvants in the hope one will work. We need good rational design based upon fundamental studies in the elderly.
These questions are important and are farreaching. The elderly are a high-risk population due to their lack of robust immune responses and many vaccines are in the pipeline for clinical studies. Fundamental studies will benefit vaccine development for West Nile Virus, RSV, and many other infectious agents.
On the otherhand, it is important to maintain vigilant real-time surveillance for shifting influenza viruses. Antigenic characterization of these viruses will aid in preparing front-line health-care workers with treatment options that include anti-viral drugs for the elderly during flu season. 
